15th International Congress on Antiphospholipid Antibodies

第十五届国际抗磷脂抗体大会

• 批准号: 9193925
• 负责人: Doruk Erkan
• 金额: $ 0.5万
• 依托单位: HOSPITAL FOR SPECIAL SURGERY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-01 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9193925
• 关键词: Address; Advisory Committees; Antibodies; Anticoagulants; Antigens; Antiphospholipid Antibodies; Antiphospholipid Syndrome; Autoimmune Diseases; Basic Science; Books; Brazil; Characteristics; Classification; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Committee Members; Communication; Communities; Congresses; Deep Vein Thrombosis; Diagnosis; Discipline; Educational workshop; Evaluation; Fetal Death; Future; Generations; Goals; Growth; Guidelines; Heart Valve Diseases; Hemolytic Anemia; Immunosuppressive Agents; Impaired cognition; Individual; Injury; International; Kidney Diseases; Knowledge; Location; Lupus; Meleagris gallopavo; Morbidity - disease rate; New York; Operative Surgical Procedures; Oral; Pathogenesis; Patient Education; Patients; Physicians; Pre-Eclampsia; Pregnancy; Research; Research Personnel; Review Literature; Risk; Risk Factors; Scientist; Special Hospitals; Stroke; Symptoms; Syndrome; Text; Thrombocytopenia; Thrombosis; Time; Venous; Voting; abstracting; base; evidence base; improved; innovation; interest; meetings; microbiome; novel; posters; premature; programs; rheumatologist; skills; symposium; targeted treatment; trophoblast

Antiphospholipid antibodies (aPL) constitute a major acquired risk factor for thrombosis. Clinical symptoms (thrombosis, pregnancy morbidity) together with aPL define the antiphospholipid syndrome (APS). Deep vein thrombosis (DVT) is the most common venous and stroke is the most common arterial thrombosis; fetal death, growth restriction, pre-eclampsia, and prematurity constitute the pregnancy morbidity. Livedo, heart valve disease, thrombocytopenia, hemolytic anemia, cognitive dysfunction, and nephropathy can also occur in aPL-positive patients. Otherwise healthy individuals or patients with other autoimmune disorders, e.g., lupus may develop aPL. The International Congress on aPL takes place every three years; traditionally, the congress has been a venue for scientists and clinicians from multiple disciplines to discuss recent innovative and important studies to prioritize research questions, and to set a roadmap for future research. During each congress, International Executive Committee Members propose and vote on a location, chair, and agenda for the next meeting. During the 14th Congress in Rio de Janeiro, Brazil in September 2013, Dr. Doruk Erkan, Associate Attending Rheumatologist at the Hospital for Special Surgery, New York, NY was elected to chair the next congress in Istanbul, Turkey in September 2016. Since 1984, 14 International Congresses on aPL have: described the clinical phenomena of APS; defined classification criteria and mechanisms based on antigen characteristics; described non-criteria manifestations; and explored new mechanisms, e.g., endothelial activation, trophoblast function, and microbiome. The field still lacks robust clinical trials, risk prediction, and precisely targeted therapies. Recent advances in both the basic and clinical sciences of APS permit us to address these deficits. At the time of the Congress, we will be poised to address new findings regarding mechanisms of antibody origin and effect, mechanisms of injury, develop new classification criteria for APS, and discuss APS clinical trials with new generation oral anticoagulants and immunosuppressive agents. The 15th International Congress on aPL will offer a comprehensive program including: evidence- based state-of-the art presentations from internationally recognized physicians and scientists; Task Force presentations; oral and poster submitted abstract presentations; meet the expert workshops; satellite symposiums; and patient education workshops. The format of the meeting is novel in that 20 teams chaired by the Scientific Planning Committee, prior to the meeting, will present tentative answers to general aPL/APS questions derived from evidence-based literature review and discussions. These teams will include points of view from different disciplines in each discussion to consolidate existing knowledge and guide new research. The meeting will produce a “State-of-the-art” APS Text Book”.

抗磷脂抗体（aPL）构成血栓形成的主要获得性危险因素。临床 症状（血栓形成，妊娠发病率）与aPL一起定义抗磷脂综合征 （APS）。深静脉血栓形成（DVT）是最常见的静脉和中风是最常见的动脉 血栓形成、胎儿死亡、生长受限、先兆子痫和早产构成妊娠 发病率青斑，心脏瓣膜病，血小板减少症，溶血性贫血，认知功能障碍， 肾病也可发生在aPL阳性患者中。其他健康个体或其他 自身免疫性疾病，例如，狼疮可发展为aPL。 APL国际大会每三年举行一次;传统上，大会 是来自多个学科的科学家和临床医生讨论最近创新和 重要的研究，以优先考虑研究问题，并为未来的研究设定路线图。在每个 大会，国际执行委员会成员提议并投票决定地点，主席和议程 下一次会议。2013年9月在巴西里约热内卢举行的第14届大会期间， Erkan是纽约州纽约特殊外科医院的副主治流变学家， 将于2016年9月在土耳其伊斯坦布尔主持下一届大会。 自1984年以来，14个国际会议上的aPL：描述了APS的临床现象; 基于抗原特征定义的分类标准和机制;描述的非标准 表现;并探索了新的机制，例如，内皮激活、滋养层功能，以及 微生物组该领域仍然缺乏强大的临床试验，风险预测和精确的靶向治疗。 APS基础和临床科学的最新进展使我们能够解决这些缺陷。在 在大会期间，我们将准备解决有关抗体起源机制的新发现 和作用、损伤机制，制定新的APS分类标准，并讨论APS的临床试验 新一代口服抗凝剂和免疫抑制剂。 第15届aPL国际大会将提供全面的计划，包括：证据- 来自国际公认的医生和科学家的最先进的演讲;工作组 介绍;口头和海报提交摘要介绍;会见专家讲习班;卫星 专题讨论会和病人教育讲习班。会议形式新颖，由20个小组主持 科学规划委员会，在会议之前，将提出一般性的初步答案， aPL/APS问题来自循证文献综述和讨论。这些团队将 在每次讨论中纳入不同学科的观点，以巩固现有知识， 指导新的研究。会议将编写一本“最先进的”APS教科书”。